TickerFacts.

Q/C Technologies, Inc. (QCLS): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$10.82M
Year ended 2025-12-31
2016-12-31: -$4.38M2017-12-31: -$5.12M2025-12-31: -$10.82M-$10.82M
2016-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$10.82Mn/a2026-04-15, From 2025-01-01
No annual figure between 2017-12-31 and 2025-12-31.
2017-12-31-$5.12Mn/m2019-04-01, From 2017-01-01
2016-12-31-$4.38Mn/a2018-07-13, From 2016-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Q/C Technologies, Inc. (QCLS)2025-12-31-$10.82Mn/a
Achieve Life Sciences, Inc. (ACHV)2025-12-31-$49.47Mn/a
Immucell Corp (ICCC)2025-12-31$1.22Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$25.37Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$9.79Mn/m
Cardio Diagnostics Holdings, Inc. (CDIO)2025-12-31-$5.91Mn/m
Volitionrx Ltd (VNRX)2025-12-31-$19.77Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.04Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31-$213.66Mn/m

Compare QCLS, ACHV, ICCC, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗